Antibody (Suitable for clinical applications)
Specification | Recommendation |
---|---|
Recommended Dilution (Conc) | 1:25-1:75 |
Pretreatment | No Pretreatment Required |
Incubation Parameters | 30 min at Room Temperature |
Prior to use, inspect vial for the presence of any precipitate or other unusual physical properties. These can indicate that the antibody has degraded and is no longer suitable for patient samples. Please run positive and negative controls simultaneously with all patient samples to account and control for errors in laboratory procedure. Use of methods or materials not recommended by enQuire Bio including change to dilution range and detection system should be routinely validated by the user.
Thymidine Phosphorylase/Platelet-Derived Endothelial Cell Growth Factor Information for Pathologists
Summary:
Thymidine Phosphorylase (also called Platelet-Derived Endothelial Cell Growth Factor or PD-ECG) regulates thymidine phosphorylation. It is involved in purine metabolism/pyrimidine metabolism and may play a role in bladder cancer, and mitochondrial neurogastrointestinal encephalomyopathy (MNGIE).
Common Uses By Pathologists:
Cancer patients often present with high levels of Thymidine Phosphorylase (TP). High intracellular staining for TP is indicative of tumor sensitivty to fluoropyrimidines such as apecitabine, Carmofur, Doxifluridine, or Fluorouracil.
Thymidine Phosphorylase/Platelet-Derived Endothelial Cell Growth Factor General Information | |
---|---|
Alternate Names | |
Curated Database and Bioinformatic Data | |
UniProt ID(s) | P04085 and P01127 |
General Description of Thymidine Phosphorylase/Platelet-Derived Endothelial Cell Growth Factor . | |
This antibody is specific to a 55 kDa protein known as platelet-derived endothelial growth factor (PD-ECGF), or thymidine phosphorylase (TP). High levels of TP/PD-ECGF are observed in cancer patients. High intracellular levels of TP/PD-ECGF are associated with increased sensitivity to fluoropyrimidine chemotherapeutic agents. |
There are no reviews yet.